Kestra Medical Technologies Ltd (KMTS) Stock Price, Quote & News

Company Profile

Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its p...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 425 279 8002

Website: kestramedical.com

Address:

3933 Lake Washington Blvd NE, Suite 200, Kirkland, United States

erevnon Apr. 9 at 8:08 PM

Goldman Sachs maintains Kestra Medical Techs $KMTS at Neutral and lowers the price target from $22 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OfficialStocktwitsUser Apr. 9 at 12:39 PM

$KMTS RSI: 50.28, MACD: -0.9387 Vol: 0.84, MA20: 19.77, MA50: 22.99 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

PenkeInvesting Mar. 19 at 7:17 PM

Fundamental analysis of $KMTS (KESTRA MEDICAL TECHNOLOGIES, LTD.) based on financial data and reported results. #KMTS

0 · Reply

BioGem Mar. 19 at 6:29 AM

$KMTS Very shortable at anything above $20. Critically wounded stock. With 58.5M shares and mkt cap of 1.17B, this is an extreme bubble valuation (Check multiples). -Revenue growth is quickly slowing QOQ. Market is niche and tough to displace legacy competitors. -Operating expenses are skyrocketing, operating losses are deeper, and cash burn is unsustainable. -Cash is quickly dwindling; they need to dilute again before any breakeven. -Many millions of vested options are in the money = dilution. -Expensive debt with hefty interest costs. -Short interest is rapidly rising. -New IPO and insiders will be selling soon.

0 · Reply

StocktwitsEarnings Mar. 17 at 8:10 PM

$KMTS Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.61 up 51.20% YoY • Reported revenue of $24.55M up 62.70% YoY • Kestra Medical Technologies Ltd. increased its FY26 revenue guidance to $93M, representing 55% growth compared to FY25, an increase from prior guidance of $91M and initial guidance of $85M.

0 · Reply

healthcareguru Mar. 12 at 5:30 PM

$KMTS cya at $2… 👎

1 · Reply

Twister8 Mar. 10 at 6:33 PM

$KMTS whats the word on the street?

0 · Reply

BillionerOfKing Feb. 26 at 4:26 AM

$KMTS Current Stock Price: $25.21

0 · Reply

OfficialStocktwitsUser Feb. 25 at 6:57 PM

$KMTS RSI: 52.33, MACD: 0.3308 Vol: 0.94, MA20: 26.04, MA50: 25.68 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

jimbecker Feb. 10 at 3:24 PM

$KMTS Stage 1b(2) Double Bottom pattern with a pivot @ $28.84.

0 · Reply

Kestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner

Mar 25, 2026, 8:00 AM EDT - 22 days ago

Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”

Mar 17, 2026, 4:01 PM EDT - 4 weeks ago

Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results

Mar 3, 2026, 6:00 AM EST - 6 weeks ago

Kestra Medical Technologies to Report Third Quarter Fiscal 2026 Financial Results on March 17

Jan 13, 2026, 6:00 AM EST - 3 months ago

Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery

Dec 30, 2025, 6:00 AM EST - 3 months ago

Kestra Medical Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:01 PM EST - 4 months ago

Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results

Dec 3, 2025, 8:00 AM EST - 4 months ago

Kestra Medical Technologies, Ltd. to Report Second Quarter Fiscal 2026 Financial Results

Dec 2, 2025, 10:11 PM EST - 4 months ago

Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares

Dec 1, 2025, 7:16 AM EST - 4 months ago

Kestra Medical Technologies, Ltd. Announces Primary Public Offering of Common Shares

Dec 1, 2025, 7:01 AM EST - 4 months ago

Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results

Nov 10, 2025, 9:52 AM EST - 5 months ago

Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra's ASSURE Device

Nov 4, 2025, 8:00 AM EST - 5 months ago

Kestra Medical Technologies to Present Late-Breaking ACE-PAS Trial Results at AHA 2025, Showcasing Next-Generation Wearable Defibrillator System

Oct 28, 2025, 8:00 AM EDT - 6 months ago

Kestra Medical Technologies to Present at the Stifel 2025 Healthcare Conference

Oct 7, 2025, 8:00 AM EDT - 6 months ago

Kestra Appoints Timothy Moran as Chief Business Officer, Strengthening Leadership Team for Next Stage of Growth

Sep 25, 2025, 8:00 AM EDT - 7 months ago

Kestra Showcases Cardiac Recovery System Platform at HFSA 2025, Redefining Sudden Cardiac Arrest Risk Management

Sep 17, 2025, 8:00 AM EDT - 7 months ago

Kestra Medical Technologies Appoints Dr. Elizabeth Kwo to Board of Directors

Sep 11, 2025, 4:01 PM EDT - 7 months ago

Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results

Aug 28, 2025, 8:00 AM EDT - 8 months ago

Kestra Medical Technologies, Ltd. to Report First Quarter Fiscal 2026 Financial Results

Jul 17, 2025, 8:00 AM EDT - 9 months ago

Kestra Medical Technologies Wins 2025 Top Workplaces Industry Award, A National Recognition

Jul 15, 2025, 4:01 PM EDT - 9 months ago

Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Jul 1, 2025, 8:00 AM EDT - 10 months ago

Kestra Medical Technologies, Ltd. to Report Fourth Quarter and Fiscal Year 2025 Results on July 15

Jun 23, 2025, 8:00 AM EDT - 10 months ago

Kestra Medical Technologies Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

Jun 5, 2025, 8:00 AM EDT - 11 months ago

Kestra Medical Technologies Announces Appointment of Conor Hanley to its Board of Directors

May 13, 2025, 8:00 AM EDT - 1 year ago

Ernst & Young LLP Names Brian Webster of Kestra Medical Technologies as an Entrepreneur Of The Year® 2025 Mountain West Award Finalist

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Kestra Medical Technologies to Participate in Upcoming Investor Conferences

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Kestra Showcases Real-World Outcomes for ASSURE WCD at Heart Rhythm 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Kestra Medical Technologies to Showcase Innovation in Sudden Cardiac Arrest Protection and Recovery at Heart Rhythm 2025

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Kestra Medical Technologies, Ltd. to Report Third Quarter Fiscal 2025 Financial Results on April 14

Mar 14, 2025, 4:05 PM EDT - 1 year ago

Kestra Medical Technologies, Ltd. Announces Full Exercise and Closing of Underwriters' Over-Allotment Option in Initial Public Offering

Mar 7, 2025, 5:30 PM EST - 1 year ago

Kestra Medical Technologies, Ltd. Announces Closing of Upsized Initial Public Offering

Mar 6, 2025, 10:43 AM EST - 1 year ago

Kestra Medical Technologies raises $202M in IPO, prices shares above expected range

Mar 5, 2025, 11:03 PM EST - 1 year ago

Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Initial Public Offering

Feb 27, 2025, 11:23 AM EST - 1 year ago

Kestra Medical Technologies aims to raise $150M in IPO

Feb 26, 2025, 8:00 AM EST - 1 year ago

Kestra Medical Technologies, Ltd. Announces Launch of Initial Public Offering

erevnon Apr. 9 at 8:08 PM

Goldman Sachs maintains Kestra Medical Techs $KMTS at Neutral and lowers the price target from $22 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OfficialStocktwitsUser Apr. 9 at 12:39 PM

0 · Reply

PenkeInvesting Mar. 19 at 7:17 PM

Fundamental analysis of $KMTS (KESTRA MEDICAL TECHNOLOGIES, LTD.) based on financial data and reported results. #KMTS

0 · Reply

BioGem Mar. 19 at 6:29 AM

0 · Reply

StocktwitsEarnings Mar. 17 at 8:10 PM

0 · Reply

healthcareguru Mar. 12 at 5:30 PM

$KMTS cya at $2… 👎

1 · Reply

Twister8 Mar. 10 at 6:33 PM

$KMTS whats the word on the street?

0 · Reply

BillionerOfKing Feb. 26 at 4:26 AM

$KMTS Current Stock Price: $25.21

0 · Reply

OfficialStocktwitsUser Feb. 25 at 6:57 PM

0 · Reply

jimbecker Feb. 10 at 3:24 PM

$KMTS Stage 1b(2) Double Bottom pattern with a pivot @ $28.84.

0 · Reply

OfficialStocktwitsUser Feb. 4 at 3:08 PM

$KMTS RSI: 68.68, MACD: -0.1171 Vol: 1.30, MA20: 24.36, MA50: 25.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

InflLink Feb. 4 at 2:01 PM

$KMTS is a manufacturer of plastic pipe and conduit for infrastructure and construction; demand is tied to non-residential construction and utility spending, which have been resilient.

0 · Reply

ZacksResearch Jan. 14 at 6:04 PM

$KMTS just made a smart move in cardiac recovery — here’s why it matters. Kestra signed an exclusive partnership with Biobeat, investing $5M to add continuous blood pressure monitoring to the ASSURE WCD during cardiac recovery. That’s a meaningful upgrade to diagnostic insight where it counts most. ⚕️📈 See how this partnership could change post-cardiac care 👉 https://www.zacks.com/stock/news/2817450/kmts-biobeat-partner-to-expand-diagnostic-insight-in-cardiac-recovery?cid=sm-stocktwits-2-2817450-teaser-28940&ADID=SYND_STOCKTWITS_TWEET_2_2817450_TEASER_28940

2 · Reply

ZacksResearch Jan. 14 at 5:04 PM

$KMTS dips 5.9% despite a promising partnership — what's happening? 🤔 Kestra is teaming up with Biobeat to enhance cardiac recovery tech, investing $5M in their Series B. Yet, shares fell, even as KMTS climbed 42.8% in 6 months. The company has a market cap of $1.37 billion and carries a Zacks Rank #4 (Sell). Find out what this means for investors here 👉 https://www.zacks.com/stock/news/2817450/kmts-biobeat-partner-to-expand-diagnostic-insight-in-cardiac-recovery?cid=sm-stocktwits-2-2817450-body-28941&ADID=SYND_STOCKTWITS_TWEET_2_2817450_BODY_28941

0 · Reply

prismmarketview Jan. 13 at 3:24 PM

Kestra Medical Technologies (Nasdaq: $KMTS) has entered a strategic collaboration with Biobeat that gives it exclusive rights to integrate Biobeat’s FDA‑cleared, cuffless ambulatory blood pressure monitoring tech into the ASSURE wearable defibrillator platform, adding 24‑hour hypertension and recovery insights for high‑risk cardiac patients. https://prismmarketview.com/kestra-medical-technologies-announces-strategic-collaboration-to-advance-interventional-oncology-innovation/

0 · Reply

GatsbyGains Dec. 25 at 8:39 AM

$KMTS Upside depends on translating ambition into measurable cadence, given the heightened sensitivity to timeline slippage. A coherent operating roadmap would be catalytic.

0 · Reply

SocioCobb Dec. 20 at 1:10 AM

$KMTS 6 mos swing… 2 banger, coming soon.

1 · Reply

erevnon Dec. 15 at 6:38 PM

Goldman Sachs maintains Kestra Medical Techs $KMTS at Neutral and raises the price target from $22 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Dec. 15 at 5:50 PM

Goldman Sachs has updated their rating for Kestra Medical Techs ( $KMTS ) to Neutral with a price target of 25.

0 · Reply

SocioCobb Dec. 12 at 10:33 PM

$KMTS yep..

0 · Reply

JarvisFlow Dec. 12 at 10:09 PM

Wells Fargo updates rating for Kestra Medical Techs ( $KMTS ) to Overweight, target set at 27 → 28.

0 · Reply

Twister8 Dec. 12 at 3:09 PM

$KMTS $30

0 · Reply

Market Cap	1.15B
Revenue (ttm)	59.82M
Net Income (ttm)	-113.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-190.25%
Debt to Equity Ratio	0.15

Volume	214,300
Avg Vol	378,238
Day's Range	N/A - N/A
Shares Out	58.37M
Stochastic %K	80%
Beta	N/A
Analysts	Strong Sell
Price Target	$27.71